Corcept Therapeutics Incorporated Net Income
| CORT Stock | USD 40.71 0.84 2.11% |
As of the 2nd of February, Corcept Therapeutics shows the Risk Adjusted Performance of (0.04), mean deviation of 3.64, and Standard Deviation of 7.43. Corcept Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Corcept Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 5.098 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 162.4 M | 170.5 M | |
| Net Income From Continuing Ops | 162.4 M | 170.5 M | |
| Net Income Applicable To Common Shares | 116.5 M | 122.3 M | |
| Net Income Per Share | 1.22 | 1.28 | |
| Net Income Per E B T | 1.00 | 1.02 |
Corcept | Net Income | Build AI portfolio with Corcept Stock |
The evolution of Net Income for Corcept Therapeutics Incorporated provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Corcept Therapeutics compares to historical norms and industry peers.
Latest Corcept Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Corcept Therapeutics Incorporated over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Corcept Therapeutics financial statement analysis. It represents the amount of money remaining after all of Corcept Therapeutics Incorporated operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Corcept Therapeutics' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Corcept Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 141.21 M | 10 Years Trend |
|
Net Income |
| Timeline |
Corcept Net Income Regression Statistics
| Arithmetic Mean | 61,201,738 | |
| Geometric Mean | 54,280,686 | |
| Coefficient Of Variation | 124.29 | |
| Mean Deviation | 68,462,373 | |
| Median | 94,181,000 | |
| Standard Deviation | 76,066,367 | |
| Sample Variance | 5786.1T | |
| Range | 214.7M | |
| R-Value | 0.92 | |
| Mean Square Error | 979.7T | |
| R-Squared | 0.84 | |
| Slope | 13,816,146 | |
| Total Sum of Squares | 92577.5T |
Corcept Net Income History
Other Fundumenentals of Corcept Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Corcept Therapeutics Net Income component correlations
Corcept Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Corcept Therapeutics is extremely important. It helps to project a fair market value of Corcept Stock properly, considering its historical fundamentals such as Net Income. Since Corcept Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Corcept Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Corcept Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Pharmaceuticals market expansion? Will Corcept introduce new products? Factors like these will boost the valuation of Corcept Therapeutics. Projected growth potential of Corcept fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Corcept Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.61) | Earnings Share 0.87 | Revenue Per Share | Quarterly Revenue Growth 0.137 | Return On Assets |
Understanding Corcept Therapeutics requires distinguishing between market price and book value, where the latter reflects Corcept's accounting equity. The concept of intrinsic value—what Corcept Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Corcept Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Corcept Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Corcept Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Corcept Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Corcept Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Corcept Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Corcept Therapeutics.
| 11/04/2025 |
| 02/02/2026 |
If you would invest 0.00 in Corcept Therapeutics on November 4, 2025 and sell it all today you would earn a total of 0.00 from holding Corcept Therapeutics Incorporated or generate 0.0% return on investment in Corcept Therapeutics over 90 days. Corcept Therapeutics is related to or competes with Halozyme Therapeutics, Abivax SA, Rhythm Pharmaceuticals, Cytokinetics, Jazz Pharmaceuticals, Caris Life, and Axsome Therapeutics. Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, o... More
Corcept Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Corcept Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Corcept Therapeutics Incorporated upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 58.23 | |||
| Value At Risk | (8.51) | |||
| Potential Upside | 6.49 |
Corcept Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Corcept Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Corcept Therapeutics' standard deviation. In reality, there are many statistical measures that can use Corcept Therapeutics historical prices to predict the future Corcept Therapeutics' volatility.| Risk Adjusted Performance | (0.04) | |||
| Jensen Alpha | (0.61) | |||
| Total Risk Alpha | (0.95) | |||
| Treynor Ratio | (0.18) |
Corcept Therapeutics February 2, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.17) | |||
| Mean Deviation | 3.64 | |||
| Coefficient Of Variation | (1,566) | |||
| Standard Deviation | 7.43 | |||
| Variance | 55.26 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.61) | |||
| Total Risk Alpha | (0.95) | |||
| Treynor Ratio | (0.18) | |||
| Maximum Drawdown | 58.23 | |||
| Value At Risk | (8.51) | |||
| Potential Upside | 6.49 | |||
| Skewness | (4.74) | |||
| Kurtosis | 31.78 |
Corcept Therapeutics Backtested Returns
Corcept Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0655, which signifies that the company had a -0.0655 % return per unit of risk over the last 3 months. Corcept Therapeutics Incorporated exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Corcept Therapeutics' Mean Deviation of 3.64, risk adjusted performance of (0.04), and Standard Deviation of 7.43 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 2.67, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Corcept Therapeutics will likely underperform. At this point, Corcept Therapeutics has a negative expected return of -0.5%. Please make sure to confirm Corcept Therapeutics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to decide if Corcept Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.4 |
Poor reverse predictability
Corcept Therapeutics Incorporated has poor reverse predictability. Overlapping area represents the amount of predictability between Corcept Therapeutics time series from 4th of November 2025 to 19th of December 2025 and 19th of December 2025 to 2nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Corcept Therapeutics price movement. The serial correlation of -0.4 indicates that just about 40.0% of current Corcept Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.4 | |
| Spearman Rank Test | -0.26 | |
| Residual Average | 0.0 | |
| Price Variance | 341.78 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Corcept Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Corcept Therapeutics Incorporated reported net income of 141.21 M. This is 58.62% lower than that of the Pharmaceuticals sector and 101.6% higher than that of the Health Care industry. The net income for all United States stocks is 75.27% higher than that of the company.
Corcept Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Corcept Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Corcept Therapeutics could also be used in its relative valuation, which is a method of valuing Corcept Therapeutics by comparing valuation metrics of similar companies.Corcept Therapeutics is currently under evaluation in net income category among its peers.
Corcept Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Corcept Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Corcept Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Corcept Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Corcept Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Corcept Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Corcept Therapeutics' value.| Shares | Amvescap Plc. | 2025-06-30 | 1 M | Norges Bank | 2025-06-30 | 981.6 K | Td Asset Management Inc | 2025-06-30 | 819.9 K | Charles Schwab Investment Management Inc | 2025-06-30 | 814.5 K | Arrowstreet Capital Limited Partnership | 2025-06-30 | 788.8 K | Td Global Investment Solutions – Td Epoch | 2025-06-30 | 765.4 K | Hpm Partners Llc | 2025-06-30 | 746.6 K | D. E. Shaw & Co Lp | 2025-06-30 | 673.1 K | Northern Trust Corp | 652.3 K | Blackrock Inc | 2025-06-30 | 12.5 M | Vanguard Group Inc | 2025-06-30 | 9.7 M |
Corcept Fundamentals
| Return On Equity | 0.17 | ||||
| Return On Asset | 0.051 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 3.78 B | ||||
| Shares Outstanding | 105.19 M | ||||
| Shares Owned By Insiders | 11.63 % | ||||
| Shares Owned By Institutions | 74.72 % | ||||
| Number Of Shares Shorted | 8.19 M | ||||
| Price To Earning | 30.07 X | ||||
| Price To Book | 6.64 X | ||||
| Price To Sales | 5.79 X | ||||
| Revenue | 675.04 M | ||||
| Gross Profit | 727.78 M | ||||
| EBITDA | 138.29 M | ||||
| Net Income | 141.21 M | ||||
| Cash And Equivalents | 370.09 M | ||||
| Cash Per Share | 3.45 X | ||||
| Total Debt | 6.94 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 8.54 X | ||||
| Book Value Per Share | 6.01 X | ||||
| Cash Flow From Operations | 198.07 M | ||||
| Short Ratio | 2.95 X | ||||
| Earnings Per Share | 0.87 X | ||||
| Price To Earnings To Growth | 0.61 X | ||||
| Target Price | 94.2 | ||||
| Number Of Employees | 500 | ||||
| Beta | 0.26 | ||||
| Market Capitalization | 4.29 B | ||||
| Total Asset | 840.55 M | ||||
| Retained Earnings | 543.74 M | ||||
| Working Capital | 330.83 M | ||||
| Current Asset | 48.98 M | ||||
| Current Liabilities | 20.88 M | ||||
| Net Asset | 840.55 M |
About Corcept Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Corcept Therapeutics Incorporated's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Corcept Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Corcept Therapeutics Incorporated based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Corcept Stock Analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.